The First Puncture Success Rate of a Novel Injeq IQ-Tip™ System in Pediatric Lumbar Punctures (IQ-LP-03)

June 12, 2023 updated by: Injeq Ltd
The investigation aims to demonstrate the first puncture success rate, as proxy of clinical benefit and clinical performance, of bioimpedance spectroscopy based spinal needle guidance method among pediatric hemato-oncology patients requiring lumbar punctures.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The primary purpose of the investigation is to demonstrate the claimed clinical benefit and safety of Injeq IQ-Tip™ system.

IQ-Tip™ is similar to common spinal needles with a custom-made stylet that enables the real-time bioimpedance measurement at the tip of the needle. The needle is connected to the analyzer device, which provides real-time CSF detection during lumbar puncture from the very tip of the needle and by these means assists conducting the medical procedure.

The investigation aims to demonstrate the first puncture success rate, as proxy of clinical benefit and clinical performance, of bioimpedance spectroscopy based spinal needle guidance method among pediatric hemato-oncology patients requiring lumbar punctures.

The investigation is conducted in the pediatric hematology and oncology units of three Finnish university hospitals

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Helsinki, Finland
        • Helsinki University Hospital, New Children's Hospital
      • Tampere, Finland
        • Tampere University Hospital
      • Turku, Finland
        • Turku University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Pediatric hemato-oncology patients whose diagnosis or treatment plan requires lumbar puncture to acquire a CSF sample or to inject drug or other substance
  • Written and signed informed consent before the procedure from the parent and/or patient depending on the age of the patient

Exclusion Criteria:

  • Parents and/or patient refusal to participate or parents and/or patient unable to give informed consent
  • Any contraindications to a lumbar puncture. Contraindications include skin infection around the puncture area, unstable hemodynamics, bleeding tendency and increased intracranial pressure

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: IQ-Tip
At most four lumbar punctures with Injeq IQ-Tip(tm) system per participant
Physician performs therapeutic or diagnostic lumbar puncture using Injeq IQ-Tip(tm) system

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The First Puncture Success Rate
Time Frame: The assessment immediately following each lumbar puncture procedure

Each individual lumbar puncture procedure is assessed as either 'first puncture success' or '-failure'.

Success rate = Successes / All procedures

Definition of the first puncture success:

  • Only one skin puncture with the needle is allowed;
  • Multiple stylet removals and reinsertions are allowed;
  • Multiple needle reorientations are allowed as long as needle tip remains inside the skin;
  • Physician must be able obtain a cerebrospinal fluid (CSF) sample that is sent to a laboratory analysis or to inject the intended medication to the patient's subarachnoid space; and
  • Physician conducting the puncture remains the same during the procedure
The assessment immediately following each lumbar puncture procedure
Rate of Serious Adverse Events
Time Frame: The assessment during four-week follow-up after each lumbar puncture procedure
Total number of serious adverse events caused by the device. Serious adverse event in probable or causal relationship to the investigational device exposure
The assessment during four-week follow-up after each lumbar puncture procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Procedures With Post-dural Puncture Headache (PDPH)
Time Frame: The assessment during 7-day follow-up after each lumbar puncture procedure

PDPH defined as headache that:

  • worsens in sitting or standing position
  • eases when lying down
  • occurs within 7 days after the lumbar puncture procedure

Possible symptoms are recording using a diary filled by the patient or parents and verified by the study nurse.

The assessment during 7-day follow-up after each lumbar puncture procedure
Percentage of CSF Samples With Greater or Equal to 10 Erythrocytes / mm^3
Time Frame: The laboratory analysis within 3 hours of the lumbar puncture
Erythrocyte (red blood cell) count according to laboratory analysis in units of 10^6/liter or 1/mm3
The laboratory analysis within 3 hours of the lumbar puncture
Percentage of Procedures With Other Complications or Adverse Events
Time Frame: The assessment during 7-day and four-week follow ups

E.g. PDPH or backache

Possible symptoms are recorded using a diary filled by the patient or parents and verified by the study nurse. Diary is an open questionaire that is intended for recording any possible complication. Possible complications are not considered as pre-determined outcome measures, with the exception of Outcome #3 (rate of PDPH)

Four-week follow up conducted by the study nurse from the hospital registers

The assessment during 7-day and four-week follow ups
Aggregate Sensitivity of CSF Detection
Time Frame: The assessment immediately following each lumbar puncture procedure

The CSF detection performance of the investigational device is assessed by the physician.

Each individual lumbar puncture procedure is classified as either 'True Positive CSF detection (TP)', 'False Negative CSF detection (FN)' or 'Procedure failed (Fail)' by the investigator.

The aggregate sensitivity = Number of TPs / Total number of procedures

The assessment immediately following each lumbar puncture procedure
Aggregate False Detection Rate of CSF Detection
Time Frame: The assessment immediately following each lumbar puncture procedure

Each individual lumbar puncture procedure is classified as either 'One or more False Positive CSF detections (FP)' or 'No False Positive CSF detections (TN)'.

The aggregate false detection rate = Number of FPs / Total number of procedures

The assessment immediately following each lumbar puncture procedure
Number of Required Attempts Per Successful Lumbar Puncture Procedure
Time Frame: The assessment immediately following each lumbar puncture procedure

In line with definition of 'the first puncture success rate', attempt is defined as: any new penetration of skin is considered a new attempt.

Lumbar puncture is considered successful irrespective of the number of punctures if the CSF sample was eventually obtained and/or the injection of medicine could be performed

The assessment immediately following each lumbar puncture procedure
Number of Failed Lumbar Puncture Procedures
Time Frame: The assessment immediately following each lumbar puncture procedure
Procedure is considered failed if physicians, even after multiple attempts, conclude that the lumbar puncture cannot be completed with available personnel or equipment due to any reason
The assessment immediately following each lumbar puncture procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Sauli Palmu, PhD MD, Tampere University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 8, 2019

Primary Completion (Actual)

August 6, 2020

Study Completion (Actual)

October 2, 2020

Study Registration Dates

First Submitted

August 23, 2019

First Submitted That Met QC Criteria

August 26, 2019

First Posted (Actual)

August 28, 2019

Study Record Updates

Last Update Posted (Actual)

June 13, 2023

Last Update Submitted That Met QC Criteria

June 12, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IQ-LP-03

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lumbar Puncture

Clinical Trials on IQ-Tip(tm) system

Subscribe